An Intervention Study on Transcranial Photobiomodulation in Children With Attention Deficit Hyperactivity Disorder
Recruiting now · Not applicable · Has a placebo group
Conditions studied: ADHD - Attention Deficit Disorder With Hyperactivity
In brief
This study aims to intervene in children and adolescents with ADHD using transcranial photobiomodulation, comparing its effects on executive function at the levels of electroencephalography (EEG), eye tracking, and cognitive behavior. The goal is to identify the most effective clinical treatment strategy for ADHD patients.
Key facts
- Study ID
- NCT06685601
- Run by
- Qilu Hospital of Shandong University
- People needed
- 60
- Starts
- 2024-12-16
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2025-07-22
Who can join
Age: 6 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age between 6 and 18 years;
- Clinically diagnosed with ADHD by a psychiatrist;
- Confirmed by the researcher (child psychiatrist) to meet the diagnostic criteria for Attention-Deficit/Hyperactivity Disorder as outlined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5);
- M.I.N.I. KID interview shows only ADHD, with no other comorbidities;
- Able to cooperate with transcranial photobiomodulation.
- The participant and their guardian fully understand the study procedures and content and agree to participate in the study, signing the informed consent form.
You may not qualify if…
- Diagnosis of other severe mental illnesses, such as schizophrenia or bipolar disorder;
- Presence of severe physical diseases or conditions, such as significant intracranial lesions, thyroid disorders, epilepsy, congenital heart disease, severe hematologic disorders, systemic lupus erythematosus, auditory or visual impairments, etc.;
- Presence of significant structural brain abnormalities on imaging studies;
- Presence of severe neurological diseases with a clear family history or potential risk;
- Presence of metal implants or a pacemaker, or holes or fractures in the skull;
- Currently undergoing other ADHD treatments (e.g., methylphenidate or other pharmacological treatments, behavioral therapy, etc.) or has discontinued such treatments for less than 2 weeks;
- Raven's Progressive Matrices IQ score < 85.
Where it is running
- Qilu Hospital of Shandong University — Jinan, Shandong, China (enrolling)
- Qilu Hospital of Shandong University — Jinan, Shandong, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.